Non-Invasive Brain Stimulation & Delirium

Status Withdrawn

Clinical Trial Summary

The purpose of this study is to examine whether non-invasive brain stimulation can be used to improve cognitive deficits in patients with delirium.

Clinical Trial Description

Data from subject's EPIC medical record will be abstracted for use in research analysis - the following elements will be reviewed: Information regarding diagnosis, age, gender, ethnicity/race, medication they are receiving as well as their past medical history, and DOSS score. The study team member will also discuss patient's mental status with their treating clinician before approaching him/her. The treating clinician will be consulted and must agree that it is appropriate for the delirious patient to be approached for enrollment. Beforehand, a clinician on the research team (Dr. Gen Shinozaki) will evaluate the subjects ability to sign consent, and thus, whether they can be approached for enrollment. When subject is identified, consent team will approach to obtain consent (and assent when applicable), email address and research demographic information. If consented, subject undergo a short CAM-ICU assessment of delirium indication - the CAM-ICU is a delirium screening tool and is not done for screening individuals out of the study, a cognitive function evaluation (MoCA), Clinical Dementia Rating (CDR), and a longer delirium evaluation (DRS-R-98) conducted by a study team member. Next, study personnel will obtain buccal swab samples and will assist with saliva samples. Trained medical staff will perform the blood draw for the blood collection sample, approximately 5-10 mL of blood per sample will be collected. If consented, subject will be asked to wear non-invasive EEG device (with two standard, clinical leads) on their head at the time of initial evaluation and up to two times daily during their hospital stay. What subjects will be asked to do/what happens in the study (in sequential order) if they meet inclusion criteria and consent, they will be asked to wear non-invasive EEG device (with two standard, clinical leads) on their head with EEG monitor capability up to three times daily while they are in the hospital. One session of non-invasive brain stimulation will be administered. Study personnel will again obtain buccal swab samples and will assist with saliva samples. Trained research team members will perform the blood draw for the blood collection sample, approximately 5-10 mL of blood per sample will be collected. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03518996
Study type	Interventional
Source	University of Iowa
Contact
Status	Withdrawn
Phase	N/A
Start date	September 1, 2018
Completion date	December 1, 2022

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04551508` - Delirium Screening 3 Methods Study
Recruiting	`NCT05891873` - Delirium in the (Neuro)Intensive/Critical Care in the Adult and Paediatric Czech Populations
Recruiting	`NCT06027788` - CTSN Embolic Protection Trial	N/A
Recruiting	`NCT04792983` - Cognition and the Immunology of Postoperative Outcomes
Recruiting	`NCT06194474` - Study on Biomarkers of Postoperative Delirium in Elderly Cardiac Surgery Patients
Completed	`NCT03095417` - Improving the Recovery and Outcome Every Day After the ICU	N/A
Completed	`NCT05395559` - Prevalence and Recognition of Cognitive Impairment in Hospitalized Patients: a Flash Mob Study
Terminated	`NCT03337282` - Incidence and Characteristics of Postoperative Cognitive Dysfunction in Elderly Quebec Francophone Patients
Not yet recruiting	`NCT04846023` - Pediatric Delirium Screening in the PICU Via EEG	N/A
Not yet recruiting	`NCT04538469` - Absent Visitors: The Wider Implications of COVID-19 on Non-COVID Cardiothoracic ICU Patients, Relatives and Staff
Not yet recruiting	`NCT03807388` - ReMindCare App for Patients From First Episode of Psychosis Unit.	N/A
Withdrawn	`NCT02673450` - PER3 Clock Gene Polymorphism, Clock Gene Expression and Delirium in the Intensive Care Unit.
Recruiting	`NCT03256500` - Transcranial Direct Current Stimulation for the Treatment of Delirium	N/A
Completed	`NCT02890927` - Geriatric-CO-mAnagement for Cardiology Patients in the Hospital	N/A
Not yet recruiting	`NCT02892968` - ED Ultrasonographic Regional Anesthesia to Prevent Incident Delirium in Hip Fracture Patients	N/A
Recruiting	`NCT03165539` - Cerebral Oxygen Desaturation and Post-Operative Delirium in Thoracic Surgical Patients
Completed	`NCT02554253` - The Impact of Ketamine on Postoperative Cognitive Dysfunction, Delirium, and Renal Dysfunction	Phase 2
Completed	`NCT02518646` - DElirium prediCtIon in the intenSIve Care Unit: Head to Head comparisON of Two Delirium Prediction Models	N/A
Recruiting	`NCT02305589` - The Clinical Changes Before and After Sugammadex in the Patients Undergoing Hip Surgery on the Aspect of Delirium	N/A
Completed	`NCT02628925` - Nu-DESC DK: The Danish Version of the Nursing Delirium Screening Scale	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Non-Invasive Brain Stimulation and Delirium

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms